

Long-term efficacy and impact of erenumab treatment on quality of life of patients participating in the APOLLON study

Authors:

Hartmut Göbel¹, Mirja Koch², Cordula Weiss³

¹ Schmerzklinik Kiel, Migräne- und Kopfschmerzzentrum, Germany

² Novartis Pharma AG, Basel, Switzerland

³ Novartis Pharma GmbH, Nuremberg, Germany

Introduction

The monoclonal antibody erenumab is an EMA and FDA approved anti-CGRP pathway treatment developed for the prevention of episodic and chronic migraine. German as well as international studies already found erenumab to be an effective treatment for the prevention of migraine with international data further confirming the long-term safety profile. However, long-term data regarding the treatment with erenumab is still limited for the German population.

Methods

APOLLON is a 128-week open-label study of erenumab treatment, assessing long-term safety and tolerability data of migraine patients in Germany who previously participated in a head-to-head trial comparing the tolerability of erenumab and topiramate (NCT03828539). Patients were allowed to pause the treatment after 12 weeks of continuous treatment with erenumab. Throughout the study, TSQM-II and HIT-6 questionnaires were completed. Monthly migraine days were collected in relation to the drug holiday.

Results

In total, 701 patients at 80 sites in Germany were included. An interim analysis (n=386, average exposure to erenumab 93.8 weeks excl. drug holidays) showed that treatment satisfaction increased over the course of the study in all observed areas: convenience, effectiveness, global satisfaction and side effects. HIT-6 data showed an improvement by more than 5 points within the first 24 weeks. The results will be completed by the final data at the end of the study in February 2023.

Conclusion

The results provide additional data on the long-term efficacy and impact on quality of life of erenumab-treated migraine patients in Germany, thus adding to the understanding of monoclonal antibody-based migraine prophylaxis.

Disclosures

Hartmut Göbel received honoraria for consulting and lectures from Allergan, Almirall, Astra Zeneca, Bayer Vital, Berlin-Chemie, Bionorica, Bristol-Myers-Squibb, Elli Lilly, Fujisawa, GlaxoSmithKline, Grünenthal, Hermal, Hormosan, Ipsen-Pharma, Janssen-Cilag, Johnson&Johnson, Krewel-Meuselbach, Klosterfrau, Lichtwer, Menarini Pharma, Merz Pharmaceuticals, Minster Pharmaceuticals, MSD, Novartis Pharma, Pfizer, Pharmacia, Sandoz, Schaper und Brümmer, Schwarz-Pharma, Teva, Weber&Weber, Smith Kline Beecham.

Mirja Koch is an employee of Novartis AG.

Cordula Weiss is an employee of Novartis Pharma GmbH.

